Minaris Advanced Therapies

Minaris Advanced Therapies: Global CDMO and Testing Partner for Cell and Gene Therapies

Minaris Advanced Therapies is a global contract development and manufacturing organisation (CDMO) and testing provider specialising in cell and gene therapies.

Formed in 2025 through the combination of Minaris Regenerative Medicine and the U.S. and U.K. operations of WuXi Advanced Therapies, Minaris Advanced Therapies operates as a unified entity under the ownership of Altaris, LLC. Headquartered in Philadelphia, Pennsylvania, the company boasts over 25 years of experience in cell therapy CDMO services and more than 40 years in biosafety testing and product characterisation. With a global footprint spanning North America, Europe, and Asia-Pacific, Minaris Advanced Therapies has released over 7,500 GMP batches and currently manufactures two commercial cell therapies while providing testing services for more than 27 commercial products.

Key Products and Services:

GMP Manufacturing Services: Clinical and commercial manufacturing of cell and gene therapy products across facilities in the U.S., Europe, and Asia, compliant with regional regulatory requirements.

Process Development and Scale-Up: Expertise in CAR-T, TIL, NK, MSC, HSC, and iPSC-based therapies, as well as AAV and LVV vectors, ensuring scalable and optimised processes.

Technology Transfer: Over 100 successful technology transfers, facilitating seamless transition from development to manufacturing.

Viral Vector Manufacturing: Comprehensive services for lentiviral, AAV, and adenoviral vector production, including early-stage development and GMP manufacturing.

Integrated Testing Services: In-house biosafety and product characterisation testing, reducing vein-to-vein time and mitigating risks associated with third-party testing.

Proprietary Technologies: Utilisation of patented platforms such as TESSA® for scalable AAV production and XOFLX™ for lentiviral vector manufacturing.

With a team of over 1,400 professionals and facilities encompassing more than 730,000 square feet, Minaris Advanced Therapies is committed to advancing cell and gene therapies from early development through to commercialisation. Their integrated approach combines manufacturing excellence with comprehensive testing services, aiming to deliver life-changing therapies to patients worldwide efficiently and safely.